These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 8640171

  • 1. Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R.
    Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
    Grochow LB.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [Abstract] [Full Text] [Related]

  • 5. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH, Choi SJ, Lee JH, Kim SE, Park CJ, Chi HS, Lee MS, Lee JS, Kim WK, Lee KH.
    Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
    McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY.
    Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
    [Abstract] [Full Text] [Related]

  • 8. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF, Weinberg K, Kohn D, Sender L, Parkman R, Lenarsky C.
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [Abstract] [Full Text] [Related]

  • 9. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringdén O, Eber S, Seger R, Ljungman P.
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation.
    Cho YH, Lim HA, Lee MH, Kim I, Lee JS, Park Sy, Kim BK, Yoon SS.
    Clin Transplant; 2007 Dec; 21(3):417-22. PubMed ID: 17488395
    [Abstract] [Full Text] [Related]

  • 14. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
    Styler MJ, Crilley P, Biggs J, Moul J, Copelan E, Topolsky D, Avalos B, Penza S, Sabol P, Downs K, Szer J, Brodsky I, Marks DI.
    Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
    [Abstract] [Full Text] [Related]

  • 15. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.
    Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Santos GW, Colvin OM.
    Cancer Chemother Pharmacol; 1989 Feb; 25(1):55-61. PubMed ID: 2591002
    [Abstract] [Full Text] [Related]

  • 19. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.
    Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, Penza SL.
    Bone Marrow Transplant; 2001 Jun; 27(11):1121-4. PubMed ID: 11551021
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.